



# Declaration of Conformity

as per Annex IV of the Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 via BSI as the Notified Body (registration no. BSI-NL 2797)

Document No.: **DOC-2022-10**

Manufacturer: **Roche Molecular Systems, Inc.  
1080 US Highway 202 South  
Branchburg, NJ 08876  
USA**

Authorized Representative: **Roche Diagnostics GmbH  
Sandhofer Strasse 116  
68305 Mannheim  
Germany**

Name, Address and Identification number of the Notified Body: **BSI Group The Netherlands B.V.  
Notified Body Number: 2797  
Say Building, John M. Keynesplein 9, 1066 EP  
Amsterdam, Netherlands**

Roche Molecular Systems, Inc. declares that the *in vitro* diagnostic medical device:

**Product Name:** **cobas<sup>®</sup> HCV**  
*Quantitative nucleic acid test for use on the **cobas<sup>®</sup> 5800/6800/8800 Systems***

**P/N:** 09040765190

*Description:*

**cobas<sup>®</sup> HCV** is an *in vitro* nucleic acid amplification test for both the detection and quantitation of hepatitis C (HCV) RNA, genotypes 1 to 6, in human EDTA plasma or serum of HCV-infected individuals.

The complete Intended Use is contained in the **cobas<sup>®</sup> HCV** Package Insert.

Complies with the requirements of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices.

This declaration is supported by the following certificates:

EC Certificate – Full Quality Assurance: CE 707974, first issued 2019-03-26, valid until 2025-05-26

EC Design-Examination Certificate: CE 708020, first issued 2019-03-26, valid until 2025-05-26

The Manufacturer agrees to develop, implement, and maintain a documented post-production monitoring process, including the notification of reportable events, under the European Medical Device Vigilance System Guidelines. As a legal manufacturer, Roche Molecular Systems, Inc., is solely responsible for the product. This declaration is issued under the sole responsibility of Roche Molecular Systems, Inc.



# Declaration of Conformity

as per Annex IV of the Directive 98/79/EC of the European Parliament and the Council of 27 October 1998 via BSI as the Notified Body (registration no. BSI-NL 2797)

Document No.: **DOC-2022-10**

Place: Tucson, AZ

Date: 19-May-2022

Place: Pleasanton, CA

Date: 17-May-2022

*Jeff Boone*

**Jeff Boone**  
Vice President, Quality Management

*Rita Hoady*

**Rita Hoady**  
Network Lead Molecular Lab  
Director, Global Regulatory Affairs